These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 17275734)

  • 1. In silico selection of active siRNA.
    Patzel V
    Drug Discov Today; 2007 Feb; 12(3-4):139-48. PubMed ID: 17275734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of target site accessibility on the design of effective siRNAs.
    Tafer H; Ameres SL; Obernosterer G; Gebeshuber CA; Schroeder R; Martinez J; Hofacker IL
    Nat Biotechnol; 2008 May; 26(5):578-83. PubMed ID: 18438400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioinformatic approaches to siRNA selection and optimization.
    Muhonen P; Holthofer H
    Methods Mol Biol; 2010; 623():93-107. PubMed ID: 20217546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational models with thermodynamic and composition features improve siRNA design.
    Shabalina SA; Spiridonov AN; Ogurtsov AY
    BMC Bioinformatics; 2006 Feb; 7():65. PubMed ID: 16472402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection and validation of optimal siRNA target sites for RNAi-mediated gene silencing.
    Luo Q; Kang Q; Song WX; Luu HH; Luo X; An N; Luo J; Deng ZL; Jiang W; Yin H; Chen J; Sharff KA; Tang N; Bennett E; Haydon RC; He TC
    Gene; 2007 Jun; 395(1-2):160-9. PubMed ID: 17449199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A structure-activity relationship study of siRNAs with structural variations.
    Chang CI; Hong SW; Kim S; Lee DK
    Biochem Biophys Res Commun; 2007 Aug; 359(4):997-1003. PubMed ID: 17577577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short interfering RNA (siRNA): tool or therapeutic?
    Cejka D; Losert D; Wacheck V
    Clin Sci (Lond); 2006 Jan; 110(1):47-58. PubMed ID: 16336204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA interference in vivo: toward synthetic small inhibitory RNA-based therapeutics.
    de Fougerolles A; Manoharan M; Meyers R; Vornlocher HP
    Methods Enzymol; 2005; 392():278-96. PubMed ID: 15644187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression silencing with 'specific' small interfering RNA goes beyond specificity - a study of key parameters to take into account in the onset of small interfering RNA off-target effects.
    Vankoningsloo S; de Longueville F; Evrard S; Rahier P; Houbion A; Fattaccioli A; Gastellier M; Remacle J; Raes M; Renard P; Arnould T
    FEBS J; 2008 Jun; 275(11):2738-53. PubMed ID: 18422646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide application of RNAi to the discovery of potential drug targets.
    Ito M; Kawano K; Miyagishi M; Taira K
    FEBS Lett; 2005 Oct; 579(26):5988-95. PubMed ID: 16153642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The design, preparation, and evaluation of asymmetric small interfering RNA for specific gene silencing in mammalian cells.
    Chang C; Hong SW; Dua P; Kim S; Lee DK
    Methods Mol Biol; 2013; 942():135-52. PubMed ID: 23027049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential design rules and enzymatic synthesis of siRNAs.
    Sioud M; Leirdal M
    Methods Mol Biol; 2004; 252():457-69. PubMed ID: 15017071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Many commonly used siRNAs risk off-target activity.
    Snøve O; Holen T
    Biochem Biophys Res Commun; 2004 Jun; 319(1):256-63. PubMed ID: 15158470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. siRNAs: their potential as therapeutic agents--Part I. Designing of siRNAs.
    Hajeri PB; Singh SK
    Drug Discov Today; 2009 Sep; 14(17-18):851-8. PubMed ID: 19540928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of a genome-wide siRNA library using an artificial neural network.
    Huesken D; Lange J; Mickanin C; Weiler J; Asselbergs F; Warner J; Meloon B; Engel S; Rosenberg A; Cohen D; Labow M; Reinhardt M; Natt F; Hall J
    Nat Biotechnol; 2005 Aug; 23(8):995-1001. PubMed ID: 16025102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. siRNA selection criteria--statistical analyses of applicability and significance.
    Bradác I; Svobodová Vareková R; Wacenovsky M; Skrdla M; Plchút M; Polcík M
    Biochem Biophys Res Commun; 2007 Jul; 359(1):83-7. PubMed ID: 17524355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiling RNA interference (RNAi)-mediated toxicity in neural cultures for effective short interfering RNA design.
    Read ML; Mir S; Spice R; Seabright RJ; Suggate EL; Ahmed Z; Berry M; Logan A
    J Gene Med; 2009 Jun; 11(6):523-34. PubMed ID: 19322910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of thiophosphate substitutions on native siRNA gene silencing.
    Li ZY; Mao H; Kallick DA; Gorenstein DG
    Biochem Biophys Res Commun; 2005 Apr; 329(3):1026-30. PubMed ID: 15752758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated siRNA design based on surveying of features associated with high RNAi effectiveness.
    Gong W; Ren Y; Xu Q; Wang Y; Lin D; Zhou H; Li T
    BMC Bioinformatics; 2006 Nov; 7():516. PubMed ID: 17129386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.